William Buxton, MD
Clinical Neurophysiology · Santa Monica, CANPI 1669495149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,273 of the $6,053 with a category attached, or 70.6%. 31 manufacturers reported payments, led by Argenx US, Inc. at 35.2% of the total.
Across 195 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$2K
- UCB, Inc.$976
- CSL Behring$409
- Acadia Pharmaceuticals Inc$386
- AbbVie$254
- AstraZeneca$250
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,72528%
- Food & beverage$4,27371%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 16 | $2,130 |
| UCB, Inc. | 53 | $976 |
| CSL Behring | 14 | $409 |
| Acadia Pharmaceuticals Inc | 25 | $386 |
| AbbVie | 10 | $254 |
| AstraZeneca(2 entities) | 9 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $230 |
| Akcea Therapeutics, Inc. | 5 | $167 |
| Lilly USA, LLC | 6 | $138 |
| Biogen | 5 | $136 |
| Catalyst Pharmaceuticals, Inc. | 5 | $122 |
| Amneal Pharmaceuticals LLC | 5 | $117 |
| Lundbeck LLC | 4 | $114 |
| Scilex Pharmaceuticals Inc. | 4 | $89 |
| Neurocrine Biosciences, Inc. | 2 | $74 |
| Alnylam Pharmaceuticals Inc. | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| Johnson & Johnson | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Medtronic | 2 | $37 |
| Grifols USA, LLC | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| GE HealthCare | 1 | $25 |
| Abbott | 1 | $23 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Amgen | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$6,053 in reported general payments places this provider in the 65th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 18 | $1,200,116 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 43 | $789,038 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $414,656 |
| ValiumDiazepam | 11 | $8,991 |
| Lidocaine | 15 | $6,203 |
| Duloxetine Hcl | 127 | $5,395 |
| Gabapentin | 121 | $3,759 |
| Pyridostigmine Bromide | 37 | $3,606 |
| Pregabalin | 63 | $1,208 |
| Mirtazapine | 11 | $1,069 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $726 |
| Prednisone | 63 | $610 |
| Sodium Chloride0.9 % Sodium Chloride | 51 | $563 |
| Paroxetine Hcl | 12 | $136 |
| Diphenhydramine Hcl | 15 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart | $2,130 | $1,200,11618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $230 | $414,65625 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $117 | $3,60637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 clinical neurophysiology providers in California.
Other clinical neurophysiology in Santa Monica
- Parastou ShilianSanta Monica$1K
- Barbara LandesmanSanta Monica$13
- Said BeydounLos Angeles$985K
- Christopher LockStanford$159K
- Srikanth MuppidiStanford$150K
- Mitchell MiglisStanford$51K
- Michael AminoffSan Francisco$41K
- Safwan JaradehStanford$34K
- Sadiq AltamimiPomona$30K
- Margaret FerrisStanford$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.